Nootropics Index - Save on smarter supplements
Nootropics>Fatty acids, lipids & phospholipids>TUDCA
Fatty acids, lipids & phospholipids

TUDCA

Tauroursodeoxycholic acid (TUDCA)

TUDCA is tauroursodeoxycholic acid, a bile-acid derivative also called taurursodiol. Retained human studies concern metabolic markers or specific clinical populations, not focus, memory, mood, or productivity in healthy adults. Compare listings by the exact ingredient, milligrams per serving, and capsule versus powder form; research doses are not a generic supplement recommendation.

Clinical ResearchLimited Human EvidenceForm Dependent Evidence
Updated August 2026/5 min read/7 citations
Reviewed by the NootropicsIndex editorial team.Method: prioritize cited human research and official safety or regulatory sources; compare retailer-listed prices without endorsing products.Affiliate disclosure
01

What is it?

Identity before price

1

TUDCA is tauroursodeoxycholic acid, a taurine-conjugated bile acid also called taurursodiol. The name identifies the compound; it does not make a retail powder or capsule equivalent to a clinical protocol.

Not a proven cognitive nootropic2
Retained human research measures metabolic markers or outcomes in specific clinical populations. It does not establish focus, memory, mood, or productivity benefits for healthy adults using generic TUDCA products.
02

Names, aliases and forms

Chemical NamesTauroursodeoxycholic acid; Taurursodiol; Tauroursodeoxycholate
AbbreviationTUDCA
03

Potential effects and evidence map

Grade E for nootropic use. The retained human literature evaluates non-cognitive outcomes in defined study contexts, including metabolic markers and primary biliary cholangitis. It does not establish focus, memory, mood, or a consumer nootropic dose, timing, or cycle for generic TUDCA products.

Effect domainMagnitudeGrade
Focus / attention2
UnknownConfidence: High

No retained human TUDCA study establishes a focus or attention benefit for healthy adults.

Note The retained trials measured non-cognitive outcomes in specific populations.

0/5
E
Memory / learning2
UnknownConfidence: High

No retained human TUDCA study establishes a memory or learning benefit for healthy adults.

Note Clinical-context findings do not establish cognitive enhancement.

0/5
E
04

Typical dosages and timing

Four-week metabolic-marker study21,750 mg/day

One four-week study in obese insulin-resistant adults used 1,750 mg/day. Another trial in primary biliary cholangitis used 250 mg three times daily for 24 weeks. These are study protocols in named populations, not a general TUDCA supplement recommendation.

05

Timing & effect horizon

Effect horizonUnknown
Unknown
No supported cognition timing2

The retained human trials tracked non-cognitive outcomes over weeks. No retained source establishes an onset, duration, or cycling schedule for focus, memory, or mood.

06

Safety, side effects and risk profile

Pregnancy and lactation evidence gap7
The registered primary-biliary-cholangitis TUDCA study excluded pregnant or nursing participants. That exclusion does not establish harm, but retained TUDCA evidence does not establish safety for pregnancy or lactation or for a retail supplement product.
Evidence uncertainty3
Confidence: High

Clinical protocols and disease-specific safety observations do not establish safety for every retail TUDCA powder or capsule.

Note Keep study context separate from generic consumer use.

2/5
E
Interaction risk5
Confidence: Medium

No retained source establishes a precise retail-supplement interaction list for TUDCA.

Note Do not infer medication compatibility from bile-acid studies or product marketing.

2/5
E
Pregnancy / lactation caution7
Confidence: High

Retained TUDCA studies do not establish safety in pregnancy or lactation.

Note The registered primary-biliary-cholangitis study excluded pregnant or nursing participants; do not infer safety from its results.

2/5
E
Clinical trial context3

In the 24-week primary biliary cholangitis trial, adverse-event rates were comparable between the TUDCA and UDCA groups. That result does not establish safety for every retail powder or capsule or for nootropic use.

16-week multiple-sclerosis study6

In a placebo-controlled progressive-multiple-sclerosis study, TUDCA 1 g twice daily for 16 weeks had treatment-related adverse events in 10 of 26 participants versus 7 of 21 placebo participants. This disease-specific finding does not establish the same frequency, severity, or risk for healthy adults or retail powders and capsules.

07

Interactions and cautions

No established consumer interaction list5

A supplement label is not evidence that a TUDCA product is compatible with a medicine. The retained human studies do not define a general retail-supplement interaction schedule.

08

Legal and regulatory status

United States - as of 20265

In the United States, FDA does not approve dietary supplements or their labels for safety and effectiveness before marketing. This is a general U.S. framework, not an ingredient-specific marketability decision; other jurisdictions can differ.

09

Practical buying and quality notes

  • Look for TUDCA or tauroursodeoxycholic acid on the label and confirm milligrams per serving. A product named UDCA is not automatically a TUDCA product, so do not compare them by price alone.1
  • Compare capsules by labelled milligrams per capsule or serving, and powders by the labelled mass. Check the exact ingredient and serving math before using a price-per-unit figure.1
10

FAQ

Does TUDCA establish a focus or memory benefit?

2

No. The retained human studies evaluate non-cognitive outcomes in specific populations, not focus, memory, mood, or productivity in healthy adults.

What TUDCA amount has been studied?

2

The retained studies used different protocols in different populations, including 1,750 mg/day for four weeks in a metabolic-marker study and 250 mg three times daily for 24 weeks in primary biliary cholangitis research. They do not create a generic consumer dose.

How long does TUDCA take, and should it be cycled?

3

No retained human source establishes a cognitive onset, duration, or cycle. Study schedules for non-cognitive clinical research should not be converted into a nootropic timing plan.

Is taurursodiol the same name as TUDCA?

1

Taurursodiol is an alternate name for tauroursodeoxycholic acid. Confirm the exact ingredient statement and amount; a shared name does not make every product or study context interchangeable.

11

References

  1. IUPHAR/BPS Guide to PHARMACOLOGY. Tauroursodeoxycholic acid ligand page.
  2. Kars M, et al. Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes. 2010;59(8):1899-1905.
  3. Ma H, et al. A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis. Medicine (Baltimore). 2016;95(47):e5391.
  4. Elia AE, et al. Tauroursodeoxycholic acid in patients with amyotrophic lateral sclerosis. European Journal of Neurology. 2016;23(1):45-52.
  5. U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements.
  6. ClinicalTrials.gov. Safety and Tolerability of Tauroursodeoxycholic Acid in Progressive Multiple Sclerosis (NCT03423121).
  7. ClinicalTrials.gov. Tauroursodeoxycholic Acid in Primary Biliary Cirrhosis (NCT01857284).
Note

This page is informational and summarizes available evidence. It is not medical advice, a recommendation, or a substitute for guidance from a qualified clinician.